Diagnostic endoscopic procedures on the upper gastrointestinal tract

Number of report

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for diagnostic endoscopic procedures on the upper gastrointestinal tract for benign and malignant diseases in outpatient settings.

Sample pages are provided for an older version of the report. Before delivery to the client, the report is updated to the current state (e.g., 2022 coding, tariffs, and policy considerations). 

The following procedures will be considered:

  • Esophagoscopy
  • Gastroscopy
  • Duodenoscopy

The report will consider both stand-alone diagnostic procedures and in combination with biopsy of lesions.

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

It is also possible to add analysis in Czech Republic, Finland, Hungary, Romania, Russia and Turkey.

Manufacturers of endoscope equipment for the upper gastrointestinal tract include:

  • Alltion (Fiber-GIS)
  • Aohua Ednoscopy (FHD-GT, VGT, VME)
  • Cogentix Medical (PrimeSight)
  • Cook Medical (Shooter Saeed, Shooter Universal Saeed)
  • Endomed Systems (Duo, Combo-2)
  • Fujifilm Holdings Corporation (Eluxeo EG, ED)
  • Huger Endoscopy System (GVE)
  • Interscope (EndoRotor)
  • IntroMedic (E.G. Scan)
  • KARL STORZ GmbH & Co. KG (Silver Scope, Tele Pack X)
  • Olympus (EVIS EXERA-Gif)
  • Pentax medical (MagniView EG, Transnasal EG, G-EYE)
  • SonoScape (EG-330 series)
  • Stryker Corporation (1588 AIM)

Table of content is not available at the moment. Report is still ongoing.


Nov 2022

On October 27, 2022, the BfArM (Federal Institute for Drugs and Medical Devices) published the final version of the 2023 OPS procedure coding classification. The OPS, together with the ICD-10-GM (International Statistical Classification of Diseases and Related Health Problems, 10th revision, German Modification), forms the basis for the reimbursement systems in outpatient and inpatient care in Germany.

Read more


Nov 2022

In the second half of October 2022, 47 new procedure codes were introduced by the Code Service of the Finnish National Health and Wellbeing Institution (THL). These codes became valid on November 1, 2022. The introduced codes are dedicated to diagnostic imaging, endoscopy, gastrointestinal, radiotherapy, pulmonary and airways, surgical procedures, and some other fields.

Read more


Oct 2022

The revised EBM (German Uniform Evaluation Standard) catalog came into force on October 1, 2022. The most significant changes concern introducing the EBM codes for several IVD tests and a new service in artificial insemination.

Read more


Jul 2022

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2022. The most significant changes concern introducing and updating multiple EBM codes for IVD tests and adjusting tariffs and content of radiotherapy services.

Read more


Jul 2022

On June 15, 2022, the National Institute for Health and Care Excellence (NICE) announced a new program called Early Value Assessment for Medtech. The program will offer a rapid assessment of digital products, devices, and diagnostics for clinical effectiveness and value for money where the evidence base is still emerging to inform NHS commissioners. The two pilot assessments for health apps will begin in June 2022 and are expected to be published in October 2022. Further topics are expected in mental health, early cancer diagnosis, and cardiovascular disease.

Read more
(we accept only company emails)